List of Noxafil drug patents
Noxafil is owned by Schering.
Noxafil contains Posaconazole.
Noxafil has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Noxafil are:
- US8263600
Noxafil was authorised for market use on 15 September, 2006.
Noxafil is available in suspension;oral dosage forms.
The generics of Noxafil are possible to be released after 01 April, 2022.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263600 | SCHERING | Antifungal composition with enhanced bioavailability |
Apr, 2022
(1 year, 2 months ago) | |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 15 September, 2006
Treatment: NA
Dosage: SUSPENSION;ORAL
NOXAFIL family patents
4
United States
2
Australia
2
Japan
2
European Union
1
Canada
1
Mexico
1
Argentina
1
Brazil
1
China
1
New Zealand
1
South Africa
1
Hungary
1
Poland
1
Peru
1
Norway
1
Taiwan
1
Korea, Republic of
Noxafil is owned by Merck Sharp Dohme.
Noxafil contains Posaconazole.
Noxafil has a total of 6 drug patents out of which 0 drug patents have expired.
Noxafil was authorised for market use on 13 March, 2014.
Noxafil is available in solution;intravenous dosage forms.
Noxafil can be used as treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; prophylaxis of invasive aspergillus and candida infections; prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised, treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised.
The generics of Noxafil are possible to be released after 27 February, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750822 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US10117951 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US8410077 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US9358297 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jun, 2031
(8 years from now) | |
| US9023790 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jul, 2031
(8 years from now) | |
| US9493582 | MERCK SHARP DOHME | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | May 31, 2024 |
| Orphan Drug Exclusivity (ODE) | Jun 17, 2028 |
| New Indication (I) | Jun 17, 2024 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Treatment: Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of a...
Dosage: SOLUTION;INTRAVENOUS
NOXAFIL family patents
19
United States
9
Japan
7
China
6
European Union
5
Korea, Republic of
5
Mexico
4
Australia
4
Canada
3
Russia
2
Israel
2
Hong Kong
2
Brazil
1
EA
1
Croatia
1
New Zealand
1
Denmark
1
Spain
1
Portugal
1
Poland
1
Slovenia
1
RS
1
Hungary
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic